Rhumbline Advisers Olema Pharmaceuticals, Inc. Transaction History
Rhumbline Advisers
- $109 Billion
- Q3 2024
A detailed history of Rhumbline Advisers transactions in Olema Pharmaceuticals, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 57,861 shares of OLMA stock, worth $585,553. This represents 0.0% of its overall portfolio holdings.
Number of Shares
57,861
Previous 59,261
2.36%
Holding current value
$585,553
Previous $641,000
7.64%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding OLMA
# of Institutions
136Shares Held
58.7MCall Options Held
141KPut Options Held
23.1K-
Bvf Inc San Francisco, CA9.14MShares$92.5 Million3.47% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY5.5MShares$55.7 Million2.37% of portfolio
-
Deep Track Capital, LP Greenwich, CT4MShares$40.5 Million1.76% of portfolio
-
Black Rock Inc. New York, NY4MShares$40.5 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct3.69MShares$37.3 Million0.12% of portfolio
About Olema Pharmaceuticals, Inc.
- Ticker OLMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,419,600
- Market Cap $409M
- Description
- Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, local...